Growing Options for RAI-Refractory Differentiated Thyroid Cancer - Episode 9
For High-Definition, Click
Beyond sorafenib and lenvatinib, other agents have also shown a clinical activity in the thyroid cancer setting, states Robert I. Haddad, MD. Some of these agents are currently available, while others are still in the testing phases.
Haddad shares the following options:
Along with vemurafenib, Haddad adds, the entire class of BRAF inhibitors is being tested in patients with BRAF mutations. Another area of ongoing investigation is immunotherapy, which may be tested as a stand-alone approach or in combination with some of the VEGF inhibitors.
Since the best approach in patients who have progressed on sorafenib and lenvatinib is unknown, Haddad notes that the next step in care would be enrollment in a clinical trial, but stresses the importance of profiling to determine which trial would be best.